ĀÜĄņĀŅĀ×

Since 2018 Mr. Klausner has served as President, CEO, and a Director of the start-up drug development company Goldilocks Therapeutics, Inc. Mr. Klausner has been a consultant to the biopharmaceutical industry since 2009. He served as Chief Executive Officer of Gem Pharmaceuticals, LLC (ā€œGemā€) from 2012 until Gemā€™s drug development assets were acquired by Monopar in 2017. In addition to his role at Gem, he was CEO of Jade Therapeutics Inc. (ā€œJadeā€) from 2012 to 2015. Previously, Mr. Klausner spent a total of 18 years at the life science venture capital firms Domain Associates and Pappas Ventures, where he was involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies.